[1-[(3aR,4R,6R,6aR)-4-(2,4-dioxopyrimidin-1-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]-2-methylbutan-2-yl]oxy-(3-hydroxypentan-3-yl)phosphinic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: [1-[(3aR,4R,6R,6aR)-4-(2,4-dioxopyrimidin-1-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]-2-methylbutan-2-yl]oxy-(3-hydroxypentan-3-yl)phosphinic acid
• 化学式: C₂₁H₃₅N₂O₉P
• 分子量: 490.5
• InChiKey: BCLTUHULEYSSON-YFAUVBGMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  144
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• MODIFIED POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY
  申请人：MODERNA THERAPEUTICS, INC.

  公开号：US20140148502A1

  公开（公告）日：2014-05-29

  The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
• IN VIVO PRODUCTION OF PROTEINS
  申请人：Moderna Therapeutics, Inc.

  公开号：US20150376648A1

  公开（公告）日：2015-12-31

  The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.